Surgery Partners（股票代码：SGRY）近日正式确认并重申其2026年的财务预期。这家医疗手术服务提供商向市场明确表态：公司预计2026年全年营收将在33.5亿美元至34.5亿美元之间浮动。与此同时，管理层对调整后息税折旧摊销前利润（Adjusted EBITDA）的指引也保持不变，设定在至少5.3亿美元的水平线上。此番表态，无疑向投资者传递了一份稳定的信号，在不确定性弥漫的市场环境中，公司正锚定清晰可见的财务航标。
Surgery Partners（股票代码：SGRY）近日正式确认并重申其2026年的财务预期。这家医疗手术服务提供商向市场明确表态：公司预计2026年全年营收将在33.5亿美元至34.5亿美元之间浮动。与此同时，管理层对调整后息税折旧摊销前利润（Adjusted EBITDA）的指引也保持不变，设定在至少5.3亿美元的水平线上。此番表态，无疑向投资者传递了一份稳定的信号，在不确定性弥漫的市场环境中，公司正锚定清晰可见的财务航标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.